SCHEMBL718379

SCHEMBL718379

Cc1c(C(Cl)C2CCCCC2)oc2ccc(F)cc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.52
RAB9A P51151 6/20 0.52
ALDH1A1 P00352 2/20 0.34
OPRK1 P41145 1/20 0.34
MAPT P10636 8/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
AKR1B1 P15121 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
ATM Q13315 1/20 0.33
GAA P10253 1/20 0.32
KDM4E B2RXH2 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
SLC6A4 P31645 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL719533 0.90 NPC1 (0.41) NPC1RAB9AALDH1A1ATMKDM4E
SCHEMBL721579 0.86 NPC1 (0.41) NPC1RAB9AALDH1A1MAPTHTT
SCHEMBL721218 0.85 MCL1 (0.43) NPC1RAB9AALDH1A1OPRK1MAPT
SCHEMBL718925 0.84 NPC1 (0.55) NPC1RAB9AALDH1A1OPRK1MAPT
SCHEMBL718548 0.83 RAB9A (0.53) NPC1RAB9AALDH1A1OPRK1MAPT
SCHEMBL718939 0.82 RAB9A (0.54) NPC1RAB9AALDH1A1MAPTL3MBTL1
SCHEMBL721329 0.81 HRH4 (0.36) NPC1RAB9AALDH1A1SLC6A4
SCHEMBL716824 0.81 NPC1 (0.48) NPC1RAB9AALDH1A1MAPTCYP2C19
SCHEMBL24755699 0.77 RAB9A (0.43) NPC1RAB9AALDH1A1OPRK1MAPT
SCHEMBL24756244 0.77 RAB9A (0.43) NPC1RAB9AALDH1A1OPRK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885ALDH1A1 504/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885ALDH1A1 504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.